#### Instructions:

- 1. Please type all information and complete all applicable sections. You may submit supplemental pages if additional lines are needed.
- 2. List all supporting documents in Appendix 3 under the pertinent section(s) of the ABAT Credentialing Application.
- 3. Completed and signed applications should be submitted to the Chair of ABAT's Credentialing Committee at ABATCredentialing@clintox.org.
- 4. Due Dates:
  - A completed electronic version (PDF) of this document is due by July 1 for all applicants.
- Fees:

Application Fee of \$200 and Examination Fee of \$300 must be received within 10 days of receipt of application.

Contact the Chair of ABAT's Credentialing Committee at <u>ABATCredentialing@clintox.org</u> with any questions about the payment process.

Payments must be submitted through the Online store at www.clintox.org using the credentialing application and exam fee options. If credentialing is denied for any reason, the \$300 examination fee will be refunded.

licant's Contact	
rmation	
Preferred Email:	
Preferred Phone:	
Preferred Mailing Address:	
By signing below, I (	) certify that the information
provided in this application and any and	d all supporting material submitted is accurate and
that all items have been completed as l	isted.
Applicant Signature	Date
Applicant Signature  For Clinical Toxicology Post-Gradu	
For Clinical Toxicology Post-Gradu  By signing below, I (	

1. Education and Licensure	
Graduate of an accredited college or university with at least a bachelor's degree	in a biomedical discipline
Degree(s):	
University(ies):	ABAT Reviewer:
Graduation Date(s):	Yes No
Healthcare professional with a valid, unrestricted license to practice in the United	ed States or Canada
Profession: License Number(s): State(s): Expiration Date(s):	
Applicants without a requirement for licensure are exempt from this criterion. Please prhold a current license to practice:	rovide explanation if not required to
	ABAT Reviewer:  Yes No
2 Taxicalany Evneriance	

#### 2. Toxicology Experience

Applicants holding a master's or doctoral degree are required to have a minimum of 2 years of full-time experience in clinical toxicology or an equivalent part-time experience.

Applicants with a bachelor's degree in a biomedical discipline must have a minimum of 5 years of full-time experience in clinical toxicology or an equivalent part time experience

The experiential requirement could be satisfied through one of the following post-graduate training program options:

 Completion of a formal, full-time 24-month training program in clinical toxicology under the direction of a DABAT or AACT fellow.

OR

 Completion of a formal, full-time 12-month training program in clinical toxicology under the direction of a DABAT or AACT fellow preceded by a 1-year formal training program in a related healthcare field (e.g. PGY1 pharmacy residency)

OR

• Completion of an ASHP accredited PGY2 Emergency Medicine pharmacy residency plus the equivalent of 1 year of full-time experience in clinical toxicology

OR

 Completion of an ASHP accredited PGY2 pharmacy residency other than Emergency Medicine plus the equivalent of 1.5 years of full-time experience in clinical toxicology

Equivalent part time experience

- 1 year full-time = 2 years at 50% time = 4 years at 25%. Time is based on an average 40-hour work week
- Candidates submitting poison information specialist work as part of their application must be certified by the AAPCC for a minimum of 3 years
- · Scholastic coursework is not considered to be professional experience

Post-Graduate Training			
	Institution & Location	Program Director	Dates
24-Month Clin. Tox. Fellowship			

ASHP Accredi					
ASHP Accreding Pharmacy Resignation Specialty:	ited PGY2				
		Toxicology-Rela	ated Employment		
Position	Employ (Institution/Facility/Dep		Tox-Related Responsibilities	on To	ek Dates
ED Clinical University Medical Cel		er; Anytown, State	Provide a description of you related responsibilities, act clinical and teaching involve	ivities, 8	Aug 2012 - current
Yes No	ed Specialist in Poison		on for Current Certificati	on:	
「otal Years of ⊺	Foxicology Experience	:		_	BAT Reviewer:
		3. Consultation	n Requirements		
OR 35 or more direc	de toxicology patient const t, bedside patient consu one/telemedicine consul	ltations + enough te	•	•	ual 50
Please complete	e Appendix 1 and, if nece	essary, Appendix 2.			
Direct, Bed	side Patient Consults	Number of Cons	ultations Completed	Date	Range
Telephone/T	elemedicine Consults				
	Total #				
	inical Toxicology Fellows rendix 1 and 2, but progr ng Committee reserves t	am director should l	keep log on file as proof	of completion of t	his requirement.

### 4. Didactic Teaching/Preceptorship

Provide evidence of a minimum of 5 presentations in clinical toxicology to learners (students or residents) for a cumulative total of at least 5 hours.

Teaching could be provided to rotators on clinical rotations, as an academic course in clinical toxicology, **OR** as grand rounds seminars.

### **Didactic Teaching**

	Lecture Title	Location	Length (hr)	Learners (Type & # attended)	Dates
	Over-the-Counter & Over the Edge — APAP, Salicylate, & NSAID Toxicities	State University College of Medicine	1 hour	80 3 <sup>rd</sup> year medical students per year	Presented monthly during EM rotation 2016 - current
1					
2					
3					
4					
5					
6					

Please list any precepting experience (providing clinical education and overseeing care provided by) of patient care clinical learners in clinical toxicology.

### **Preceptorship**

	Institution (University & Program)	Rotation Title	Rotation Description	Dates
	State University College of Nursing	Poison Center/Toxicology	Community Health elective for nursing students in last semester of BSN program	2015 – 2019 academic years
1				•
2				
3				
4				

	ABAT Re	

### 5. Research Protocols

Provide evidence of designing and conducting at least one research study in clinical toxicology. (This can include related studies such as surveillance of adverse drug events, drug interactions, etc., quality assurance activities regarding the assessment and treatment of poisoned patients, or medication use evaluations related to clinical toxicology.)

	Study Title	Role (i.e. PI, Coordinator, etc.)	Brief Description of St		IRB pproved (Y/N)	Dates
	Please Pick Your Poison	Principal Investigator	Prospective descriptive revieus suspected human exposures		Υ	6/21/19 - ongoing
1						
2						
•				,	ABAT Rev	viewer:
		6. Researc	h Publications			
	ride evidence of authoring at le y) in clinical toxicology (or rela				ries or rese	earch
	y) in diffical toxicology (or role	·	in APA Format			
		(https://aj	pastyle.apa.org/)			
	Garrard A, Sollee DR, Butterfield ethanol to the os		tholf RL. Validation of a pre-existil 2012;50(7):562-566. doi:10.3109			ontribution of
1						
2						
3						
* A m	plicants that have completed a 1 or 2	voor elipioel tovicele av felloweb	in under the direction of an ADAT	or FAACT		
are	not required to have a manuscript sub	mitted and accepted for publica	ation by the application deadline.		ABAT Re	
	fellowship director's signature on this a manuscript of publishable quality is	in progress.		as completed	Yes	No No
rov	ide evidence of having author		arch Publications	y that are n	ot the recul	t of receare
	lucted by the applicant (e.g. bo	ook chapters, review artic	cles, case reports, etc.).	y tilat ale ili	ot the resul	lorresearc
	<ul> <li>Four newsletter articles (o</li> <li>Newsletter articles may or</li> </ul>		1 publication. of the two required publica	tions: the ot	her needs	to be a peer
	reviewed submission.			•		·
		Citation		Pu	blication 1	
	"Chloroquine and Hydroxychloroqu fro	m the Maryland Poison Center			Newsletter	
	Meier, Kathryn H, Rodenticides, Mis Olson KR et al, eds. McGraw-Hill C			Peer-reviewe	ed Book Chap	ter/Monograph
1						
2						
3						
4						

ABAT Reviewer:

Yes No Page 5

#### 8. Professional Presentations

Provide evidence of having given at least 4 presentations on clinical toxicology to other professionals (e.g. poster presentation, continuing education programs, platform presentation, grand rounds seminar, webinars, etc.)

	Title	Presentation Type	Description (& CME, CNE, or ACPE applicable)		Date
	Toxic Jeopardy	Live CE presentation	Presented at 6 <sup>th</sup> Annual Pills & Killl – Toxicology in Review in for CME, CNE, & ACPE UAN ; 19-090-L01-P	El Paso, TX	3/28/2019
1					
2					
3					
4					
5				_	
				ABAT Revi	ewer:

#### 9. Editorial/Reviewer Duties

Serve as an editor, editorial board member, or peer reviewer for health care or toxicology-related publication/journal OR

Peer reviewer for abstracts submitted to a toxicology-related conference

Other editorial/reviewer activity will be considered based on information provided by the candidate (e.g. expert witness work, Pharmacy & Therapeutics Committees, monographs for drug databases, etc.). More complete descriptions and supporting documents may be referenced here and added in Appendix 3.

	Journal or Conference*	Total Peer Reviews	Date Range
Conference Abstract Peer Reviewer	TSHP Alcalde Southwest Leadership Conference     Pills & Thrills that Kill – Toxicology in Review	80 10	2015-2019 2018-2020
Editor			
Editorial Board Member			
Journal Peer Reviewer			
Conference Abstract Peer Reviewer			

<sup>\*</sup>You may enter more than one journal or conference per type of editor/reviewer category. Be sure to provide complete information for each entry.

<b>Expert Witness</b>	Brief Description of Case & Your Involvement	Date

\*Candidates who have completed a 1 or 2 year fellowship under the direction of an ABAT or FAACT who have not been directly involved in an active case can meet this requirement by reviewing previous expert witness work completed by the director and discussing the ethics surrounding such work (as evidenced by the director's signature on this application confirming what is documented in this chart).

Pharmacy &

**Therapeutics** 

1

2

**Brief Description of Involvement in P&T** 

(include any MUE or drug class monographs you prepared)

Committee					
orug Ionographs for Databases	Database		Brief Description		Date
scribe other acti	vities below:				
				ABAT Reviewer	r:
				☐ Yes ☐ No	
				Parent Parent	
		10. Comm	ittaa Wayk		
Com	mittee	Organization	Role & Responsibilities		ate nge
SPI Co	ommittee	AAPCC	NACCT Planning Sub-committee Chair – r for identifying topics and speakers then ob required documents for CE approvals for N Symposium	responsible otaining the	5-2018
			Γ	ABAT Reviewer:	
					•
				Yes No	
		11. Communi	ity Education		
	a minimum of 5 p ted to clinical toxic	resentations (or other e	ducational activity including media ap	pearances) to th	ne lay
Topic/ Pr	esentation	Audience	Brief Description	D:	ate
	Practices during		Interview by KVIA-7 regarding exposure	risks from	
	VID-19	General TV audience	cleaning products and poison prevention	tips during 05/0	08/20

cleaning products and poison prevention tips during COVID-19 pandemic

Date

3			
4			
5			
		ABAT Rev	iewer:

Reference #1 Information	
Name:	
Email:	
Mailing Address:	
Reference #2 Information	
Name:	
Email:	
Phone:	
Reference #3 Information	
Name:	
Email:	
Phone:	
Mailing Address:	

Appendix 1. Direct, Bedside Patient Consults

	Appendix 1. Direct, Bedside Patient Consults					
	Date (M/Yr)	Consult Requested By:	Title or Topic	Scenario	Recommendation / Monitoring	Follow-Up
	05/19	ED MD	APAP ER	15 y F ingested handful of 650mg Tylenol 10hrs prior to arrival	Start IV NAC, trend APAP q4h x3, continue NAC if any APAP crosses nomogram line	Rec repeat NAC bag #3 due to lingering APAP levels after 21hr NAC. Discharged on HD3.
1						
2						
3						
5						
6						
7						
8						
9						
10						
11 12						
13						
14						
15						
16						
17						
18						
19						
20 21						
22						
23						
24						
25						
26						
27						
28 29						
30						
31						
32						
33						
34						
35						
36						
37 38						
39						
40						
41						
42						
43						
44						
45						
46 47						
47						
49						
50						
			l .	1	ı	l .

Appendix 2. Telephone/Telemedicine Consults

	Appendix 2. Telephone/Telemedicine Consults					
	Date (M/Yr)	Consult Requested By:	Title or Topic	Scenario	Recommendation / Monitoring	Follow-Up
	06/19	ICU Medical Team	Chronic digoxin	68 Y F with multiple myeloma & A Fib on dig, presents to ED with UTI, SCr=4, hypotension and bradycardia, digoxin=4.0. K 5.8	Unclear home dig dosing. Repeat dig level now. Give first vial of Digoxin Fab, more Fab pending result.	Patient recovered after 4 day hospitalization
1						
2						
3						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						
16 17						
18						
19						
20						
21						
22						
23						
24						
25						
26						
27						
28 29			-			
30						
31						
32						
33						
34						
35						
36						
37						
38						
39						
40 41						
41						
43						
44						
45						
			1		1	

### **Appendix 3. Supporting Documents**

Please list supporting documents included as attachments to any and all of the credentialing requirements:

1. Education and Licensure

2.	Toxicology Experience
3.	Consultations
4.	Didactic Teaching/Preceptorship
5.	Research Protocols
6.	Research Publications
7.	Non-Research Publications
8.	Professional Presentations
9.	Editorial/Review Duties
10.	Committee Work
11.	Community Education